Manuel Hidalgo, Md, Phd
Vice President for Healthcare Outcomes Policy and
Oncology and Molecular Radiation Sciences
Agroservis - Limited liability company
Norway
Biography
Manuel Hidalgo, MD, PhD joined the CNIO in 2009 to lead the GI Cancer Clinical Research Unit. Dr. Hidalgo is a founding member of the pancreatic cancer research team – a clinical trials group focusing on novel therapeutics for pancreatic cancer. He has participated in the clinical development of more than 30 novel anticancer agents and led the early clinical trials with erlotinib and temsirolimus – two recently approved drugs.
Research Interest
His work has contributed to the incorporation of molecular endpoints in early clinical trials. His group pioneered the utilisation of personalised xenograft models for drug screening, biomarker development and personalised cancer treatment. He has published more than 220 papers in peer-reviewed journals and his work has been funded by the NCI, AACR, and ASCO.
